| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC0142 |
| Trial ID | NCT01573572 |
| Disease | Age-Related Macular Degeneration | Diabetic Macular Edema | Retinal Vein Occlusion |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | Macugen|pegaptanib|EYE001 |
| Phase | Phase4 |
| Recruitment status | Completed |
| Title | A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium |
| Year | 2007 |
| Country | United States |
| Company sponsor | Bausch & Lomb Incorporated |
| Other ID(s) | EOP 1024 |
| Cohort 1 | |||||||||||||
|
|||||||||||||